The NN104 RHAPSODY primary manuscript has been published in the January 2019 print issue of Annals of Neurology. As the abstract notes, this trial was important for three reasons:
- It was the first trial of a neuroprotectant for acute ischemic stroke in a trial design allowing thrombectomy, thrombolysis, or both
- It demonstrated that all four doses of 3K3A-APC considered in the trial met the definition for safety and tolerability
- It demonstrated a trend towards lower hemorrhage rate, which was consistent with trends observed in prior animal studies. This trend requires confirmation in a larger study
Congratulations to Dr. Lyden and the NN104 RHAPSODY team. The success of this academic/industry partnership is another major statement of the many benefits that NeuroNEXT brings to the conduct of high-quality phase II studies in the neurosciences.
External Source: